News from biovaxys technology corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 14, 2021, 08:00 ET BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology

BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers...

Mar 31, 2021, 08:00 ET BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T

BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer...

Mar 24, 2021, 08:00 ET BioVaxys Expands Intellectual Property Portfolio

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "the Company"), the world leader in haptenized antigen vaccines for...

Mar 18, 2021, 07:55 ET BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer...

Mar 15, 2021, 08:00 ET BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer...

Mar 01, 2021, 08:00 ET BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer...

Feb 22, 2021, 08:00 ET BioVaxys Announces Appointment To Its Scientific Advisory Board

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine...

Feb 18, 2021, 08:00 ET BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") announced today that it has signed a Term Sheet ("Term...

Feb 16, 2021, 08:00 ET BioVaxys Announces Broadening Of Share Liquidity With DTCC Full Service Eligibility

BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys" or "Company") is pleased to announce that the company has been approved for...

Feb 12, 2021, 08:00 ET BioVaxys Announces Appointment of Corporate Advisor

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or "the Company") is pleased to announce that is has appointed Shmuel Farhi as Corporate ...

Feb 10, 2021, 08:07 ET BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC:L MNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer...

Feb 02, 2021, 08:18 ET BioVaxys SARS-CoV-2 Vaccine Candidate BVX-0320 Stimulates Neutralizing Antibodies To Live COVID-19 Virus

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to announce that its Covid-19 vaccine candidate,...

Jan 28, 2021, 08:00 ET Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to announce that it has initiated the clinical...

Jan 25, 2021, 08:04 ET BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Features Observation Of Neutralizing Antibodies To SARS-CoV-2 Advancement Of Viral Vaccine Platform And T-cell Diagnostic To Address Emerging...

Dec 21, 2020, 08:00 ET BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens

BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys") announced today that further analysis of the data from a preclinical animal...